These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21818672)

  • 1. The human papillomavirus (HPV) vaccine and cervical cancer: uptake and next steps.
    Sheinfeld Gorin SN; Glenn BA; Perkins RB
    Adv Ther; 2011 Aug; 28(8):615-39. PubMed ID: 21818672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M; Jasani B; Fiander A
    Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
    Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
    Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is use of the human papillomavirus vaccine among female college students related to human papillomavirus knowledge and risk perception?
    Licht AS; Murphy JM; Hyland AJ; Fix BV; Hawk LW; Mahoney MC
    Sex Transm Infect; 2010 Feb; 86(1):74-8. PubMed ID: 19841004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
    Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
    Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
    Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
    Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil.
    Haupt RM; Sings HL
    J Adolesc Health; 2011 Nov; 49(5):467-75. PubMed ID: 22018560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mothers' preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam.
    Poulos C; Yang JC; Levin C; Van Minh H; Giang KB; Nguyen D
    Soc Sci Med; 2011 Jul; 73(2):226-34. PubMed ID: 21733609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability of human papillomavirus vaccine for males: a review of the literature.
    Liddon N; Hood J; Wynn BA; Markowitz LE
    J Adolesc Health; 2010 Feb; 46(2):113-23. PubMed ID: 20113917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
    Flaherty DK; Alkhateeb FM
    Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus vaccine: a paradigm shift for pediatricians.
    Jenson HB
    Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
    Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
    Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provider perceptions of barriers and facilitators of HPV vaccination in a high-risk community.
    Javanbakht M; Stahlman S; Walker S; Gottlieb S; Markowitz L; Liddon N; Plant A; Guerry S
    Vaccine; 2012 Jun; 30(30):4511-6. PubMed ID: 22561142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer.
    Ault K; Reisinger K
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S26-8. PubMed ID: 18162242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming the barriers to HPV vaccination in high-risk populations in the US.
    Downs LS; Scarinci I; Einstein MH; Collins Y; Flowers L
    Gynecol Oncol; 2010 Jun; 117(3):486-90. PubMed ID: 20303156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The uptake of Human Papillomavirus (HPV) vaccine among adolescent females in the United States: a review of the literature.
    Bartlett JA; Peterson JA
    J Sch Nurs; 2011 Dec; 27(6):434-46. PubMed ID: 21750234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus vaccine uptake and barriers: association with perceived risk, actual risk and race/ethnicity among female students at a New York State university, 2010.
    Bednarczyk RA; Birkhead GS; Morse DL; Doleyres H; McNutt LA
    Vaccine; 2011 Apr; 29(17):3138-43. PubMed ID: 21376797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.
    Monsonego J; Cortes J; Greppe C; Hampl M; Joura E; Singer A
    Vaccine; 2010 Nov; 28(51):8065-72. PubMed ID: 20971114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.